Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5

Benzinga Newsdesk www.benzinga.com Neutral 49.6%

Neg 0% Neu 49.6% Pos 0%

Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.